Chinese biotech financing accelerated this week as D3 Bio and Sanegene each announced >$100M rounds, and European surfaceome startup Disco closed a €36M seed to advance target discovery. Investors deployed large growth and seed capital across discovery platforms, sequencing-enabled diagnostics and surface‑targeting therapeutic pipelines. The financings point to durable venture appetite in platform companies that link discovery algorithms to druggable targets and diagnostics. D3 Bio and Sanegene’s rounds underscore China’s continued capital flow into domestic innovators, while Disco’s raise signals European investor interest in surfaceome-enabled antibody discovery. Market watchers will track hiring, IND timing and translational proof points over the next 12–18 months.